Spots Global Cancer Trial Database for autologous hematopoietic stem cell transplant (hsct)
Every month we try and update this database with for autologous hematopoietic stem cell transplant (hsct) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL | NCT00490529 | Lymphoma, Mantl... | CpG-MCL vaccine PF-3512676 Vaccine-primed ... Autologous hema... Rituximab Standard induct... Cyclophosphamid... Filgrastim | 21 Years - 70 Years | Stanford University | |
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL | NCT00490529 | Lymphoma, Mantl... | CpG-MCL vaccine PF-3512676 Vaccine-primed ... Autologous hema... Rituximab Standard induct... Cyclophosphamid... Filgrastim | 21 Years - 70 Years | Stanford University | |
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. |